biostudies-literatureUnknown89Joshi SR<h4>Background</h4>There is an unmet need for antiretrovirals with novel mechanisms of action that can provide additional options for people with HIV-1. DOMINO evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults naive to antiretroviral therapy.<h4>Methods</h4>This partially blinded, multicentre phase 2b trial enrolled people with HIV-1 from 54 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm³ who were naive to antiretroviral therapy. Participants were centrally randomised to receEClinicalMedicine103567https://www.ebi.ac.uk/biostudies/studies/S-EPMC12675029biostudies-literatureEfficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.PMC12675029Joshi SRChernova OEFishman CNunez SACordova EJeffrey JLJoshi ALataillade MBainbridge VOyee JMitha EZhang YMan CPotthoff ARamgopal MLlibre JMCastagna AWynne BfalseEfficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.<h4>Background</h4>There is an unmet need for antiretrovirals with novel mechanisms of action that can provide additional options for people with HIV-1. DOMINO evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults naive to antiretroviral therapy.<h4>Methods</h4>This partially blinded, multicentre phase 2b trial enrolled people with HIV-1 from 54 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm³ who were naive to antiretroviral therapy. Participants were centrally randomised to rece2025-01-01T00:00:00Z2025 Nov2026-06-05T23:37:20.173Z2026-05-23T03:13:50.268ZS-EPMC126750294135733010.1016/j.eclinm.2025.103567